Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of PARP inhibitor 2X-121 in metastatic breast cancer selected by 2X-121 DRP
2017-003508-39Phase 2Terminated
- Sponsor
- Allarity Therapeutics
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of stenoparib in breast cancer, sponsored by Allarity Therapeutics. Primary endpoint: Clinical benefit rate (CBR). Started Jan 2018; status: terminated.
02
Drugs
stenoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-003508-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003508-39.